Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 7, 2023

Details for Patent: 9,616,096

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 9,616,096 protect, and when does it expire?

Patent 9,616,096 protects QBRELIS and is included in one NDA.

This patent has ten patent family members in eight countries.

Summary for Patent: 9,616,096

Title:	Lisinopril formulations
Abstract:	Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
Inventor(s):	Mosher; Gerold L. (Kansas City, MO), Miles; David W. (Kansas City, MO)
Assignee:	SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO)
Application Number:	15/268,095
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,616,096
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,616,096

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF HYPERTENSION	See Plans and Pricing
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				METHOD OF TREATING HYPERTENSION	See Plans and Pricing
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF HEART FAILURE	See Plans and Pricing
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF MYOCARDIAL INFARCTION	See Plans and Pricing
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION	See Plans and Pricing
Azurity	QBRELIS	lisinopril	SOLUTION;ORAL	208401-001	Jul 29, 2016		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				ACUTE MYOCARDIAL INFARCTION	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 9,616,096

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	3003274	See Plans and Pricing
China	108472252	See Plans and Pricing
China	112972370	See Plans and Pricing
European Patent Office	3368012	See Plans and Pricing
European Patent Office	3960156	See Plans and Pricing
Spain	2886869	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Medtronic

Colorcon

Dow

Mallinckrodt

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.